Intra-Cellular Therapies Aktie
121,00
EUR
±0,00
EUR
±0,00
%
126,82
USD
-0,18
USD
-0,14
%
Werbung
Intra-Cellular Therapies Aktie Analyse
08.02.18 | Intra-Cellular Therapies Outperform | RBC Capital Markets | |
15.12.17 | Intra-Cellular Therapies Buy | Canaccord Adams | |
16.12.16 | Intra-Cellular Therapies Overweight | Cantor Fitzgerald | |
29.09.16 | Intra-Cellular Therapies Outperform | RBC Capital Markets | |
17.09.15 | Intra-Cellular Therapies Outperform | RBC Capital Markets | |
14.04.15 | Intra-Cellular Therapies Outperform | RBC Capital Markets |
Werbung
Werbung